SRTS · XBRL financial data

Sensus Healthcare financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SRTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	3,898	12,567*	10,663	9,239	8,839	13,066*	8,344	7,315	6,884	4,939*	3,394	2,290
Revenue from contracts with customers	—	year only	10,663	9,239	8,839	13,066*	8,344	7,315	6,884	4,939*	—	—
Cost of revenue	1,909	—	—	3,816	3,599	—	—	—	—	—	—	—
Cost of goods and services sold	1,909	4,736*	4,001	3,816	3,599	5,960*	3,990	4,412	4,171	3,042*	2,403	1,521
Gross profit	1,989	7,831*	6,662	5,423	5,240	7,106*	4,354	2,903	2,713	1,897*	991	769
Research and development	1,083	677*	926	866	863	1,561*	2,606	1,471	1,819	1,882*	1,590	1,109
Selling, general and administrative	—	year only	1,579	1,579	1,573	2,416*	2,208	1,986	1,917	1,762*	2,043	1,786
General and administrative	1,511	952*	1,579	1,579	1,573	—	—	—	—	—	—	—
Total operating expenses	3,884	2,254*	3,775	3,441	3,745	5,380*	7,000	4,846	5,282	5,045*	5,349	3,949
Operating income (loss)	(1,895)	5,577*	2,887	1,982	1,495	1,726*	(2,646)	(1,943)	(2,569)	(3,148)*	(4,358)	(3,180)
Interest income	277	—	214	209	279	—	—	—	—	—	—	—
Interest expense	—	year only	(214)	(209)	—	year only	(184)	(183)	—	—	—	—
Other income (expense)	319	228*	214	209	279	230*	184	183	160	155*	125	117
Income tax expense (benefit)	(125)	1,595*	827	579	559	410*	110	(723)	(1,466)	174*	(1,607)	5,686
Net income (loss)	(1,451)	4,210*	2,274	1,612	1,215	1,546*	(2,572)	(1,037)	(943)	(3,167)*	(2,626)	(8,749)
Earnings per share, basic USD per share	(0.09)	0.26*	0.14	0.10	0.07	0.09*	(0.16)	(0.06)	(0.06)	(0.19)*	(0.16)	(0.53)
Earnings per share, diluted USD per share	(0.09)	0.26*	0.14	0.10	0.07	0.09*	(0.16)	(0.06)	(0.06)	(0.19)*	(0.16)	(0.53)
Weighted average shares, basic thousands of shares	16,270	16,271*	16,295	16,298	16,321	16,335*	16,342	16,320	16,320	16,326*	16,463	16,462
Weighted average shares, diluted thousands of shares	16,270	16,298*	16,318	16,333	16,346	16,440*	16,342	16,320	16,320	16,326*	16,463	16,462

Balance sheet

CSV

Fiscal quarters (SRTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	20,487	23,148	14,728	18,972	22,558	22,056	19,072	22,162	24,453	22,083	18,327	15,186
Accounts receivable	6,883	10,645	19,625	18,293	16,961	19,731	18,018	12,622	9,336	6,041	3,578	1,680
Inventory	13,202	11,861	14,720	12,769	11,968	10,097	9,923	12,405	13,040	14,563	16,500	18,459
Total current assets	45,858	49,528	53,913	54,473	54,806	56,738	54,196	52,219	50,205	45,892	42,590	37,677
Property and equipment, net	421	464	633	712	1,635	1,997	2,678	2,714	2,522	1,976	2,314	2,748
Right-of-use asset	820	774	726	679	630	581	633	574	513	452	390	329
Total assets	50,546	53,710	57,273	58,163	59,858	62,165	60,210	58,852	58,295	53,039	51,546	41,259
Total current liabilities	5,231	4,212	5,473	4,682	5,210	5,885	6,725	6,413	6,803	4,722	5,859	4,327
Lease liability, non-current	648	596	553	503	451	398	408	343	277	209	141	69
Total liabilities	5,959	4,868	6,066	5,262	5,727	6,338	7,176	6,788	7,101	4,941	6,004	4,396
Retained earnings (accumulated deficit)	2,577	6,787	9,061	10,673	11,888	13,434	10,862	9,825	8,882	5,715	3,089	(5,660)
Total stockholders' equity	44,587	48,842	51,207	52,901	54,131	55,827	53,034	52,064	51,194	48,098	45,542	36,863
Total liabilities and equity	50,546	53,710	57,273	58,163	59,858	62,165	60,210	58,852	58,295	53,039	51,546	41,259
Common shares outstanding (cover page) thousands of shares	16,382	16,394	16,393	16,389	16,390	16,495	16,445	16,440	16,425	16,462	16,462	16,462

Cash flows

CSV

Fiscal quarters (SRTS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,451)	4,210*	2,274	1,612	1,215	1,546*	(2,572)	(1,037)	(943)	(3,167)*	(2,626)	(8,749)
Stock-based compensation	67*	52*	91	65*	45*	122*	79	67*	73*	76*	70	70*
Depreciation and amortization	60*	—	—	—	—	—	—	—	—	—	—	—
Net cash from operating activities	442*	2,668*	(8,187)	4,230*	3,953*	(827)*	(2,677)	3,117*	2,295*	(2,207)*	(3,753)	(3,133)*
Purchases of property and equipment	11*	0*	233	3*	337*	(297)*	7	27*	4*	158*	3	8*
Net cash from investing activities	31*	0*	(233)	(3)*	(337)*	297*	(7)	(27)*	(4)*	(158)*	(3)	(8)*
Share repurchases	—	0*	—	—	—	—	300	0*	0*	0*	—	—
Net cash from financing activities	(39)*	(7)*	—	—	(30)*	28*	(300)	0*	0*	(5)*	—	—

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.